HC Wainwright Has Bearish Forecast for BioNTech Q4 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Research analysts at HC Wainwright decreased their Q4 2026 earnings per share estimates for BioNTech in a report issued on Monday, June 16th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $0.88 for the quarter, down from their previous forecast of $0.90. HC Wainwright has a “Buy” rating and a $138.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share.

Other analysts also recently issued reports about the stock. Leerink Partners set a $112.00 target price on shares of BioNTech in a report on Monday, June 2nd. Truist Financial restated a “buy” rating and issued a $155.00 price target (up previously from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a research report on Thursday, May 22nd. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a research report on Saturday, June 7th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $137.86.

BioNTech Price Performance

Shares of BioNTech stock opened at $104.40 on Tuesday. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $101.79 and its two-hundred day moving average price is $107.84. The stock has a market cap of $25.10 billion, a PE ratio of -30.71 and a beta of 1.29.

Hedge Funds Weigh In On BioNTech

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in shares of BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after acquiring an additional 150 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of BioNTech during the 4th quarter valued at $1,118,000. Charles Schwab Investment Management Inc. grew its holdings in shares of BioNTech by 39.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company’s stock valued at $21,349,000 after acquiring an additional 53,319 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in shares of BioNTech by 24.6% during the 4th quarter. Vontobel Holding Ltd. now owns 21,385 shares of the company’s stock valued at $2,437,000 after acquiring an additional 4,227 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of BioNTech during the 4th quarter valued at $584,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.